Lawsuit News Alerts
Carboplatin Side Effects Lawsuit Information
Chemotherapy drug Carboplatin, used by hundreds of patients in their fight against cancer, can create a number of life-threatening health complications. Sold under the trade names Paraplatin by Bristol-Myers Squibb and generic Carboplatin, the cancer drug leads the list of adverse events associated with chemotherapy medication. At least 376 adverse event reports were registered with the FDA MedWatch system in 2011 while the manufacturers received complaints of more than 150 instances of serious Carboplatin side effect injuries. The 2011 QuarterWatch surveillance report on prescription drug side effects prepared by the Institute for Safe Medication Practices ranks the drug No. 4 on the list of most reported medications for side effects.
Often considered to be a safer drug, with less side effects, compared to more powerful chemotherapy drug Cisplatin, Carboplatin is associated with the increased risk of myelosuppression, immune system problem, and adverse hematologic effects. In the past one decade, the FDA has received a large number of complaints linking the chemotherapy drug to several complications, such as lower respiratory tract infection, pathogen-linked infections, hematology disorders, renal disorders, and decreased WBC count. Carboplatin can also cause fatal health problems, including interstitial lung infection, pyrexia, myelodysplastic syndrome, reduced platelet count, sepsis, and malignant neoplasm progression.
History of Carboplatin
Carboplatin Fact File
Generic Name: Carboplatin, Trade Name: Paraplatin
Carboplatin Use: Chemotherapy drug to treat ovarian cancer and secondary use to treat lung, neck, and other types of cancers
Manufacturer: Bristol-Myers Squibb, NYC, USA
Year of Approval: March 1989; generic version in October 2004
MedWatch Complaints: 376 directly and 140 by manufacturers
Major Carboplatin Side Effects: Nephrotoxicity, myelosuppression, neutropenia, kidney problems, immune system problem, ear damage, respiratory tract infection, gastrointestinal perforation, etc.
Carboplatin Warning: FDA dosage communication October 2010;
Carboplatin Recalls: Hospira Carboplatin injection recall, July and Dec 2012, following discovery of crystals
Zestril Side Effects Lawsuit Information
Zestril Side Effect Injury Lawsuits
More than one-third of adults in the United States suffer from high blood pressure and consequent health disorders, according to the Centers for Disease Control and Prevention. About 70 percent of these use medication to treat hypertension. Zestril, Prinivil, and generic Lisinopril are among the most commonly used prescription drugs by hypertensive adults. However, ACE inhibitors, such as Zestril, can be fatal, and their side effects may lead to life-threatening conditions.
According to the QuarterWatch prescription drug surveillance report, Zestril accounted for the fifth highest number of side effect injuries in 2011. The FDA MedWatch program received at least 351 consumer and doctor complaints regarding serious Zestril side effect injuries. The Institute for Safe Medication Practices, which monitors, assesses, and reports prescription drug side effect injuries quarterly and annually has found more than 274 Zestril side effect injuries discovered by manufacturers during post-marketing surveys in 2011.
Zestril carries a FDA black box warning for serious angioedema and liver failure. The hypertension drug has also been linked to neurological problems, respiratory distress, birth defects, hyponatremia, severe allergic reaction, and a number of other health problems.
History Of Zestril
Zestril Fact File
Generic Name: Lisinopril
Zestril Use: ACE inhibitor; treatment of high blood pressure, myocardial infarction; prevention of heart attack and congestive heart failure; prevention of diabetes-induced renal complications
Manufacturer: British-Swedish pharmaceutical AstraZeneca, London
Year of Approval: November 1995
MedWatch Complaints: 351 on MedWatch and 274 by manufacturers
Major Zestril Side Effects: Death, liver damage, acute liver failure, angioedema, neurological impairments, respiratory distress
Zestril Warning: Angioedema and hepatic failure (May 2005); FDA alert for birth defect (June 2006); safety label changes on nervous system disorder (May 2009)
Zestril FDA Approval
Pradaxa Side Effect Injury Lawsuits
Anticoagulant Pradaxa accounted for the highest number of prescription drug side effect injuries reported in 2011, according to the QuarterWatch report of the Institute for Safe Medication Practices. The FDA received 3,781 Pradaxa adverse event reports, including 542 deaths, 2,367 hemorrhages, 644 heart attacks, 291 kidney impairments, and 15 cases of liver failure, that year, which was almost three times higher than side effect injuries associated with Coumadin, the most reported Warfarin blood thinner.
A meta-analysis of MedWatch adverse event reporting system in 2012 highlighted that internal bleeding caused by Pradaxa side effects could pose a five-fold higher risk of death than any Warfarin-based anticoagulant. Pradaxa led to 956 side effect injury complaints, including 178 deaths, in the second quarter of 2012, which was far higher than 214 adverse events and 14 deaths linked to other Warfarin blood thinners reported during the same period.
Pradaxa Fact File
|Generic Name: Dabigatran|
|Pradaxa Use: Anticoagulant, blood thinner;|
|Manufacturer: Boehringer Ingelheim, based in Ingelheim am Rhein, Germany|
|Year of Approval: October 2010|
|MedWatch Complaints: 817 directly from consumers and doctors and 2,964 from manufacturers|
|Pradaxa Side Effects: Internal hemorrhages, heart attacks, renal impairments, Stomach pain, and liver failure; More than 500 deaths in the last two years|
|Pradaxa Lawsuits: More than 200 product liability lawsuits filed in various federal courts and counting|
History of Pradaxa
The FDA approved anticoagulant Pradaxa in October 2010 to prevent blood clotting in patients who undergo hip or knee replacement surgeries. The blood thinner produced by German drug maker Boehringer Ingelheim contains thrombin inhibitor Dabigatran, which forestalls the blood from coagulating. The drug is also used to treat patients suffering from non-valvular atrial fibrillation and at the risk of heart stroke.
Manufacturer Boehringer Ingelheim claims that Pradaxa is better than other Warfarin-based blood thinners used by patients and that there is no need for frequent tests to keep tab on blood international normalized ratio (INR). However, researchers have found that Pradaxa does not offer any significant benefit for patients already treated with Warfarin and those who have good INR. Rather, the drug has added health risks, such as hypertension, congestive heart failure, liver damage, and kidney disorders, which neutralize its benefits. There is no medication at present that can reverse the effects of Pradaxa in the case of internal bleeding, and this puts patients at the risk of death. In the last two years, Pradaxa caused over 500 deaths and more than 3,000 severe and debilitating injuries, making it one of the most unsafe drugs in the United States.
Most Reported Drug Side Effects
Drug Adverse Reaction Injuries Side Effects Drugs Most Reported for Side Effects
About 2 to 4 million US residents suffered from severe, debilitating, and fatal injuries caused by prescription drug side effects in 2011, according to the Institute for Safe Medication Practices, which monitors drug adverse events in the United States. The annual data published by its QuarterWatch surveillance program shows that the FDA got 179,855 serious drug side effect injury reports in 2011, which include 21,002 reports directly from healthcare professionals and consumers through the MedWatch system and 158,853 adverse events corroborated by manufacturers. The numbers released are 9.4 percent or 15,386 instances more than annual drug injury cases reported in the previous year.
Top 10 Drugs Reported for Side Effect Injuries
The Institute for Safe Medication Practices has identified 10 drugs that led the list of adverse events associated with prescription medication in 2011. Anticoagulant medication Pradaxa, produced by German drug maker Boehringer Ingelheim, tops the list, followed by warfarin-based anticoagulant Coumadin - manufactured and marketed by Bristol-Myers Squibb. Antibiotic Levaquin, Cipro, and Bactrim, chemotherapy drugs Carboplatin and Cisplatin, ACE inhibitor Zestril, anti-cholesterol drug Zocor, and antidepressant Cymbalta complete the remaining places on the list of 10 drugs most frequently reported for their safety issues, target of consumer groups, and subject to litigations.
Stryker Rejuvenate Hip Replacement Implant Recall Lawsuit
Stryker Rejuvenate Hip Implant Lawsuits
On January 25, a Stryker Rejuvenate class action lawsuit was filed in a south Florida federal court seeking free treatment and medical monitoring for people implanted with the recalled metal hip replacement devices. Michigan-based Stryker Orthopedics recalled its metal Rejuvenate Modular hip implants in June 2012 following widespread reports of metal poisoning, local tissue reactions, pain, premature device failure, and early modular-neck junction corrosion attributed to its design defects. The FDA received as many as 60 complaints on the hip implant failure, metallosis, infection, and bone necrosis in the four months preceding the recall.
An estimate released by Stryker Orthopedics in January 2013 puts the total costs the manufacture has to pay for personal injury lawsuits filed following the hip system recall at $390 million.
GranuFlo Lawsuit and NaturaLyte Lawsuit
GranuFlo and NaturaLyte Lawsuits
On January 25, 2013, a 38-year-old Louisiana man filed a product liability lawsuit against Fresenius Medical Care, claiming he had suffered from life-threatening dialysis injuries. According to the GranuFlo and NaturaLyte lawsuit filed at the Louisiana east district court, Ronnie Glasper suffered from heart stroke, heart attack, and severe pain following hemodialysis treatment at Fresenius clinic in Ferriday. He was administered with two dialysates NaturaLyte and GranuFlo, manufactured by Fresenius, which have been linked to the substantial risk of cardiovascular problems, metabolic imbalance, and wrongful death.
The hemodialysis lawsuit is one of the three dozen similar litigation cases filed against Fresenius in various federal courts across the United States. The number of lawsuits is expected to grow into hundreds, and the motion for MDL consolidation has already been filed. Internal memos leaked in March 2012 revealed that Fresenius was aware of hundreds of deaths caused by improper doses of NaturaLyte and GranuFlo at its clinics in 2010, but continued to treat patients with these hemodialysis solutions without any warning or disclosure of safety concerns.
DePuy Metal On Metal Hip Implant Lawsuit Updates
DePuy ASR Hip Implant Lawsuit: Latest Updates
DePuy ASR hip lawsuits seeking product liability damages against Johnson & Johnson are finally slated to undergo trial at various state and federal MDL courts. According to Bloomberg, more than 10,000 claims were filed across the United States until August 2012 and many more are expected to join. The manufacturer was forced to recall 37,000 DePuy ASR hip implants in the United States in August 2010 following the rising number of complaints citing device failure, metallosis, and other health complications. The hip implants shed metal debris, leading to surrounding tissue death and rising blood metal ion level, which put users at the risk of serious health complications.
DePuy ASR Hip Lawsuit: Court Trials
Nap Nanny Recall Lawsuit
Nap Nanny Recliner Recall Following Deaths and Injuries
On December 27, 2012, four retailers announced recall of 150,000 Baby Matters Nap Nanny recliners following an appeal by the U.S. Consumer Product Safety Commission (CPSC). The market withdrawal was expected following an administrative complaint filed by the CPSC on December 5 seeking the product recall on the ground that defective design and lack of adequate warning on them increase the risk of infant injury and death. In the last 28 months, the CPSC has received 72 reports of infant injuries caused by fall from these recliners. The manufacturer continues to stand by its product and is yet to issue a recall on its own.
There were reports of at least five deaths and 92 injuries caused by infants falling out of first and second generation Nap Nanny recliners and Nap Nanny Chill baby recliners prior to the recall issued by Buy Buy Baby, Babies R Us, Diapers.com, and Amazon.com. The present Baby Matters Nap Nanny recliner recall was second in the last two years after about 30,000 recliners were recalled in July 2010 following similar infant injury and death complaints.
CPSC Warning and Administrative Complaint
According to the CPSC, three Nap Nanny recliner models - Generation One, Generation Two, and Chill - have defects in their design, label warnings, and instruction manuals, which put infants at the risk of grievous injury and death. Its earlier recall in 2010 following infant injuries and death forced Baby Matters to introduce a second-generation version of these inclined foam beds fitted with fabric cover. However, indentation on which the babies are placed continues to remain defective and harness belts have failed to protect infants. The incidents of death and injury have gone up manifold, forcing the federal regulator to determine that warnings and instructions are insufficient to protect babies.
On December 5, 2012, the CPSC filed an administrative complaint asking for suspension of sale and a nationwide recall of purchased Nap Nanny and Nap Nanny Chill recliners. It claims that dangerous design defects were behind deaths and injuries caused by infants falling out of these foam beds and seeks an order for the manufacturer to notify all distributors and consumers about the serious risks posed by the product. If the complaint is accepted, Baby Matters will be required to recall products and refund the full value of purchased recliners to consumers.
The administrative complaint by the CPSC is rare and the fourth in the last 11 years. Two of the previous instances include recall of two child-linked products, Zen Magnet and Buckyball desk toys, in August.
- Parent Category: Lawsuit News Alerts
- Category: Securities Fraud And Business Lawsuit Information
AIG Rejects Shareholder Lawsuit
AIG Rejects Call To Join Shareholder Lawsuit Challenging 2008 Federal Bailout
American financial giant AIG has decided against joining the shareholder lawsuit challenging the terms of the $182 billion federal rescue package to save it from bankruptcy in 2008. The $25 billion litigation filed in 2011 contends that the terms of the bailout, including 92% equity stake surrendered to the government at high interest rates, were detrimental to the interest of shareholders. Popularly known as Greenberg lawsuit, it also accuses the government of unfairly burdening the insurance company facing its worst financial crisis.
The board of American International Group met in New York on January 9, 2013, and rejected the representation made by former CEO and lead plaintiff Maurice Greenberg to join the shareholder lawsuit against the U.S. Government. Though the reason behind the decision was not made public, it is widely believed that fear of widespread public backlash deterred AIG board from joining the litigation. In December 2012, the government sold back the shares it held under the rescue package conditions, and the New Year day saw AIG starting the nationwide “Thank You, America” campaign, expressing gratitude toward taxpayers for bailing it out from the crisis.
Background of Greenberg Lawsuit
The Federal Bailout
In September 2008, downgrading of credit rating agencies following $13.2 billion reported half-yearly losses forced a liquidity crisis on AIG. The U.S. Federal Reserve announced $85 billion secure credit under the Federal Reserve Act to avert collapse of the company. Its Board of Governors authorized the Federal Reserve Bank of New York to formulate a plan to infuse credit-liquidity over 24-months. All AIG assets, including stocks of regulated and non-regulated subsidiaries were collateralized. The federal government got 79.9 percent equity stake and the right to set aside dividend payments to shareholders.
- Parent Category: Lawsuit News Alerts
- Category: Wages And Compensation Lawsuit Lawyer Information
Employment Wage Overtime Lawsuit
Dole Food Faces Class Action for Wage Violations
On December 26, workers of California-based Dole Food Company filed a wage violation class action lawsuit accusing the employer of not paying for the substantial time they had to spend in putting on the mandatory sanitary clothing. Dole’s food safety policies make it mandatory for workers to wear lab coats, gloves, and hairnets and sanitize hands and shoes before reaching their workstations. The lawsuit filed in the 1s claimed that the practices of the food processing multinational are contrary to California law. According to him, workers have to dress on and off the elaborate sanitary suits during lunch and rest break. However, the company considers it a part of worker’s break time, which is unfair and violation of state labor laws granting lunch and rest convenience for industrial workers, he alleges.
The wage class action lawsuit demands that Dole should pay employees for the time they need to sanitize hands and put on elaborate protective gears. It argues that a worker is required to do so because of Dole’s standard safety practices that ultimately help the food multinational win commercial benefits and consumers, and the time spent by workers contributes to this success.
Dole Food Company, a $7 billion multinational food processor, has 36,000 full-time and 23,000 part-time workers worldwide. It has been subject to many lawsuits for violations of labor laws and standard workplace security practices in the past. In February 2009, the court ordered Dole to pay $2.5 million to Nicaraguan workers who claimed to become sterile following their exposure to banned pesticides at its banana plantations. The movie “Bananas!” by Swedish film maker Fredrik Gertten was based on the plight of thee workers employed by Dole.
Mirena IUD Lawsuit Mirena Birth Control IUD Recall Lawsuit
Mirena IUD Perforation Defect IUD Birth Control Lawsuit
On December 17, 2012, a Kentucky woman filed a Mirena IUD birthe control lawsuit against Bayer, alleging that the defective design of the contraceptive device caused it to migrate from its place of implant that resulted in acute abdominal pain and other health problems. She had to undergo surgery to remove the Mirena birth control IUD device located at the right posterior. Three similar Mirena IUD lawsuits filed in November 2012 by women from Florida, Ohio, and California claimed that the plaintiffs suffered from uterine wall perforation following the migration of intrauterine contraceptives they were implanted with. The women had to undergo hysterectomy to remove the birth control devices and suffered from no-viable pregnancy.
These lawsuits are part of dozens of product liability litigations filed across the United States alleging injuries and serious health problems caused by the Mirena IUD. All such claims belittle insistence of the manufacturer that the contraceptive is safer and hassle free to be inserted directly into the uterus, where it remains in place and prevents pregnancy for up to five years.
Subaru Recall Lawsuit
Subaru Recalls 634,000 Vehicles Citing Potential Fire Hazard
On January 3, 2013, Japanese car maker Subaru announced recall of 634,000 vehicles, including sedans, crossovers, and wagons, sold in the United States, citing potential fire hazard caused by an electrical problem. The National Highway Traffic Safety Administration has confirmed to have received at least 10 reports of smoke and melting caused by short-circuit in the wiring and connectors of the puddle lamp located under doors of Subaru vehicles when exposed to electrolytic moisture. The Subaru car fire hazard recall covers all 2010 and 2011 Legacy and Outback models, some Tribeca SUVs made from 2006 to 2012, and selected Forester crossovers manufactured between 2009 and 2012.